NBIX vs SOBR · P/E 45, rev $1.77B vs rev $108.1K
Neurocrine Biosciences Inc (NBIX) versus Sobr Safe Inc (SOBR) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Sobr Safe Inc (SOBR) is a scientific & technical instruments company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SOBR revenue for 2026-06-30 was $108.1K. Net income was -$5.4M. Revenue was up 36.8% from 2026-03-31 to 2026-06-30. SOBR currently screens at market cap $2.6M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SOBR currently screens at market cap $2.6M.
Not investment advice. Open the NBIX and SOBR stock pages for the full models.
Not investment advice.